​
​

Rigel Pharmaceuticals (RIGL) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Rigel Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$116.88M

Latest Revenue (Q)

$55.31M

Main Segment (Y)

Gross product sales

Rigel Pharmaceuticals Revenue by Period

Rigel Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31--2.79%
2022-12-31--19.43%
2021-12-31-37.39%
2020-12-31-83.21%
2019-12-31-33.20%
2018-12-31-892.62%
2017-12-31--78.00%
2016-12-31--29.46%
2015-12-31-250.24%
2014-12-31-15.38%
2013-12-31-217.78%
2012-12-31--52.63%
2011-12-31--96.20%
2010-12-31-16566.67%
2009-12-31-100.00%
2008-12-31--100.00%
2007-12-31--62.36%
2006-12-31-102.55%
2005-12-31-249.17%
2004-12-31--57.19%
2003-12-31--29.98%
2002-12-31-3.17%
2001-12-31-15.77%
2000-12-31-47.13%
1999-12-31--

Rigel Pharmaceuticals generated $116.88M in revenue during NA 2023, up -2.79% compared to the previous quarter, and up 262.60% compared to the same period a year ago.

Rigel Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-09-30-50.12%
2024-06-30-24.74%
2024-03-31--17.48%
2023-12-31-27.22%
2023-09-30-4.64%
2023-06-30-3.13%
2023-03-31--49.16%
2022-12-31-128.82%
2022-09-30--24.85%
2022-06-30-78.18%
2022-03-31--18.00%
2021-12-31--5.26%
2021-09-30--17.98%
2021-06-30--67.58%
2021-03-31-339.12%
2020-12-31-0.33%
2020-09-30-14.78%
2020-06-30--71.27%
2020-03-31-262.08%
2019-12-31--26.16%
2019-09-30-100.41%
2019-06-30--17.56%
2019-03-31--66.65%
2018-12-31-678.15%
2018-09-30-172.24%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31--100.00%
2017-09-30-100.00%
2017-06-30--100.00%
2017-03-31-19.47%
2016-12-31--20.21%
2016-09-30--56.25%
2016-06-30-70.89%
2016-03-31--41.09%
2015-12-31--34.31%
2015-09-30-150.69%
2015-06-30-138.02%
2015-03-31--73.60%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31--100.00%
2013-12-31-100.00%
2013-09-30--100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30--100.00%
2012-06-30-100.00%
2012-03-31-100.00%
2011-12-31--100.00%
2011-09-30-1002.53%
2011-06-30-100.00%
2011-03-31-100.00%
2010-12-31--100.00%
2010-09-30-46.15%
2010-06-30-1416.62%
2010-03-31-334.80%
2009-12-31-100.00%
2009-09-30-100.00%
2009-06-30-100.00%
2009-03-31-100.00%
2008-12-31-100.00%
2008-09-30-100.00%
2008-06-30-100.00%
2008-03-31--100.00%
2007-12-31--

Rigel Pharmaceuticals generated $55.31M in revenue during Q3 2024, up 50.12% compared to the previous quarter, and up 205.71% compared to the same period a year ago.

Rigel Pharmaceuticals Revenue Breakdown

Rigel Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Discounts and allowances-----
Government contracts-----
Gross product sales-----
Milestone-----
Product sales, net-----
Revenues from collaborations-----
License revenues-----
Research and development services and others-----
Development milestones-----
Contract revenues from collaborations-----
Government contract-----
License-----
Contract Revenues From Collaborations-----
Development Milestones-----
Discounts And Allowances-----
Gross Product-----
Research And Development Services And Others-----
Product-----

Rigel Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Gross product sales (66.47%), Product sales, net (47.14%), Revenues from collaborations (5.19%), Government contracts (0.50%), Milestone (0.03%), and Discounts and allowances (-19.33%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Discounts and allowances--------------------
Revenues from collaborations--------------------
Product sales, net--------------------
License--------------------
Gross product sales--------------------
Contract revenues from collaborations--------------------
Government contract--------------------
Research and development services and others--------------------
Development milestones--------------------
License revenues--------------------
Contract Revenues From Collaborations--------------------
Research And Development Services And Others--------------------
Product--------------------
Gross Product--------------------
Government Contract--------------------
Discounts And Allowances--------------------
Development Milestones--------------------
Research And Development Services--------------------

Rigel Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Gross product sales (54.03%), Product sales, net (37.35%), Revenues from collaborations (15.71%), License (9.59%), and Discounts and allowances (-16.69%).

Rigel Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RIGLRigel Pharmaceuticals--
CDTXCidara Therapeutics--
FBIOFortress Biotech--
PIRSPieris Pharmaceuticals--
NBRVNabriva Therapeutics--
VECTVectivBio--
OCUPOcuphire Pharma--
EIGREiger BioPharmaceuticals--
MREOMereo BioPharma Group--
XFORX4 Pharmaceuticals--
RVPHReviva Pharmaceuticals--
DAWNDay One Biopharmaceuticals--
ZURAZura Bio--
ABOSAcumen Pharmaceuticals--
INZYInozyme Pharma--
LPTXLeap Therapeutics--
ELEVElevation Oncology--
TERNTerns Pharmaceuticals--
IMMXImmix Biopharma--
ENVBEnveric Biosciences--
EFTReFFECTOR Therapeutics--

RIGL Revenue FAQ

What is Rigel Pharmaceuticals’s yearly revenue?

Rigel Pharmaceuticals's yearly revenue for 2023 was $116.88M, representing a decrease of -2.79% compared to 2022. The company's yearly revenue for 2022 was $120.24M, representing a decrease of -19.43% compared to 2021. RIGL's yearly revenue for 2021 was $149.24M, representing an increase of 37.39% compared to 2020.

What is Rigel Pharmaceuticals’s quarterly revenue?

Rigel Pharmaceuticals's quarterly revenue for Q3 2024 was $55.31M, a 50.12% increase from the previous quarter (Q2 2024), and a 96.58% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $36.84M, a 24.74% increase from the previous quarter (Q1 2024), and a 37.03% increase year-over-year (Q2 2023). RIGL's quarterly revenue for Q1 2024 was $29.53M, a -17.48% decrease from the previous quarter (Q4 2023), and a 13.29% increase year-over-year (Q1 2023).

What is Rigel Pharmaceuticals’s revenue growth rate?

Rigel Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -21.68%, and for the last 5 years (2019-2023) was 97.14%.

What are Rigel Pharmaceuticals’s revenue streams?

Rigel Pharmaceuticals's revenue streams in c 23 are Discounts and allowances, Government contracts, Gross product sales, Milestone, Product sales, net, and Revenues from collaborations. Discounts and allowances generated $-42.764M in revenue, accounting -19.33% of the company's total revenue, up 34.46% year-over-year. Government contracts generated $1.1M in revenue, accounting 0.50% of the company's total revenue Gross product sales generated $147.06M in revenue, accounting 66.47% of the company's total revenue, up 35.51% year-over-year. Milestone generated $75K in revenue, accounting 0.03% of the company's total revenue Product sales, net generated $104.29M in revenue, accounting 47.14% of the company's total revenue, up 35.94% year-over-year. Revenues from collaborations generated $11.49M in revenue, accounting 5.19% of the company's total revenue

What is Rigel Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Rigel Pharmaceuticals was Gross product sales. This segment made a revenue of $147.06M, representing 66.47% of the company's total revenue.